Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04563195
Other study ID # 56505
Secondary ID
Status Withdrawn
Phase Phase 2/Phase 3
First received
Last updated
Start date February 1, 2022
Est. completion date January 2025

Study information

Verified date January 2022
Source Stanford University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To demonstrate that tibulizumab (LY3090106) treatment improves the mean unstimulated salivary flow rate or the salivary gland total ultrasound score (TUS) in primary Sjogren's syndrome patients at week 12 compared to the baseline visit.


Description:

This will be a single-site, open-label study in patients with primary Sjogren's syndrome. All patients will receive tibulizumab (LY3090106) 300mg subcutaneously every 2 weeks for a total of 12 weeks. Primary Sjogren's syndrome was selected as a relevant patient population based on the mechanism of action of the molecule and the current understanding of the pathogenesis of the disease. An open-label design was chosen based on practical considerations regarding the number of patients that could be recruited. Although open-label studies are subject to bias, objective primary endpoints were intentionally chosen to minimize this concern. The goal of this study is to demonstrate that tibulizumab (LY3090106) treatment improves the mean unstimulated salivary flow rate or the salivary gland total ultrasound score (TUS) in primary Sjogren's syndrome patients at week 12 compared to the baseline visit.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date January 2025
Est. primary completion date December 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: - Men and women 18-85 years of age - Confirmed diagnosis of primary Sjogren's syndrome by the 2016 ACR-EULAR classification criteria for primary Sjogren's syndrome - All women (regardless of childbearing potential) must test negative for pregnancy at the time of screening - Women must also agree to use a reliable method of birth control from screening until 12 weeks following last dose of study drug unless they are not of child bearing potential - Have stimulated whole salivary flow rate of greater than or equal to 0.10 ml/minute - Have a salivary gland total ultrasound score (TUS) of less than or equal to 9 (on a 0-11 point scale) Exclusion Criteria: - Currently enrolled in a clinical trial involving an investigational product or off-label use of a drug - Concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study - Have received any nonbiologic investigational product within 30 days or 5 half-lives (whichever is longer) of their baseline (Day 1) visit - Have received any biologic investigational product within 3 months or 5 half-lives (whichever is longer) of their baseline visit, or any leukocyte depleting agent within 12 months of baseline - Have disease-modifying antirheumatic drug (DMARD) or immunosuppressive use as follows: - ANY treatment with a janus kinase (JAK) inhibitor (including but not limited to tofacitinib, baricitinib, upadacitinib, or filgotinib) within 28 days prior to baseline or planned treatment with a JAK inhibitor during the study - UNSTABLE PRESCRIBED DOSE of other synthetic DMARDs (eg, hydroxychloroquine, methotrexate, leflunomide, or sulfasalazine) within 28 days prior to baseline or if the dose of drug is planned to be increased during the study (stable prescriptions are allowed) - ANY treatment with cytotoxic or immunosuppressive drugs including but not limited to cyclophosphamide, mycophenolic acid, azathioprine, cyclosporine, sirolimus, or tacrolimus within 28 days prior to screening or planned treatment during the study - Have had treatment with biologic DMARDs as follows: Etanercept, adalimumab, or anakinra <4 weeks before baseline or planned treatment during the study - Have had treatment with biologic DMARDs as follows: Infliximab, certolizumab pegol, golimumab, abatacept, or tocilizumab <8 weeks before baseline or planned treatment during the study - Are persons who have previously completed or withdrawn from this study

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
tibulizumab (LY3090106)
subcutaneous injections of 300mg every 2 weeks over a period of 12 weeks

Locations

Country Name City State
United States Stanford University Palo Alto California

Sponsors (1)

Lead Sponsor Collaborator
Matthew C. Baker

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary whole unstimulated sialometry change in unstimulated salivary flow baseline
Primary whole unstimulated sialometry change in unstimulated salivary flow week 12
Primary salivary gland ultrasound change in salivary gland ultrasound score baseline
Primary salivary gland ultrasound change in salivary gland ultrasound score week 12
Secondary ESSDAI change in the ESSDAI disease activity score
The EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) is a physician administered questionnaire containing 12 organ-specific domains designed to measure disease activity. The ESSDAI score is obtained by addition of the twelve domain scores. Each domain score is obtained by multiplying the activity level with the domain weight. The maximum theoretical ESSDAI score is 123 and the minimum score is 0. A higher score means more disease activity (worse outcome).
baseline
Secondary ESSDAI change in the ESSDAI disease activity score
The EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) is a physician administered questionnaire containing 12 organ-specific domains designed to measure disease activity. The ESSDAI score is obtained by addition of the twelve domain scores. Each domain score is obtained by multiplying the activity level with the domain weight. The maximum theoretical ESSDAI score is 123 and the minimum score is 0. A higher score means more disease activity (worse outcome).
week 12
Secondary ESSPRI change in the ESSPRI disease activity score
The EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI) is a patient completed questionnaire to assess subjective patient symptoms, which includes 3 domains (dryness, fatigue, and pain). The ESSPRI score is calculated by averaging the three domains with a maximum severity score of 10 and minimum score of 0. A higher score means more disease activity (worse outcome).
baseline
Secondary ESSPRI change in the ESSPRI disease activity score
The EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI) is a patient completed questionnaire to assess subjective patient symptoms, which includes 3 domains (dryness, fatigue, and pain). The ESSPRI score is calculated by averaging the three domains with a maximum severity score of 10 and minimum score of 0. A higher score means more disease activity (worse outcome).
week 12
Secondary whole stimulated sialometry change in stimulated salivary flow rate baseline
Secondary whole stimulated sialometry change in stimulated salivary flow rate week 12
Secondary Schirmer I test change in the Schirmer I test baseline
Secondary Schirmer I test change in the Schirmer I test week 12
Secondary MRI change in MRI (parenchymal architecture scored 0 to 4 and sialography scored 0 to 4) baseline
Secondary MRI change in MRI (parenchymal architecture scored 0 to 4 and sialography scored 0 to 4) week 12
Secondary PET change in PET (parotid and submandibular gland SUVmax) baseline
Secondary PET change in PET (parotid and submandibular gland SUVmax) week 12
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT00920179 - Confocal Microscopy and Lacrimal Gland in Sjogren's Syndrome N/A
Recruiting NCT04544722 - Clinical Study of Jianfei Kangfu Cao in the Treatment of pSS-ILD N/A
Withdrawn NCT02027298 - Abatacept for Patients With Inflammatory Arthritis Associated With Sjögren's Syndrome: an Open-Label Phase II Study Phase 2
Withdrawn NCT05781451 - Anti-BTLA Agonist Therapy in Subjects With Primary Sjogren's Syndrome Phase 2
Recruiting NCT05673993 - A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome Phase 3
Completed NCT00542763 - Mycophenolate Sodium Treatment in Patients With Primary Sjogren's Syndrome Phase 1